期刊
PHARMACOTHERAPY
卷 27, 期 6, 页码 860-873出版社
WILEY
DOI: 10.1592/phco.27.6.860
关键词
acute respiratory distress syndrome; ARDS; acute lung injury; ALI; inflammation; coagulation; fibrinolysis; tissue factor pathway inhibitor; activated protein C; thrombomodulin; antithrombin; heparin; plasminogen activators; t-PA; u-PA
资金
- NHLBI NIH HHS [R42 HL071439, HL071439, R41 HL071439, R42 HL071439-02] Funding Source: Medline
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are associated with high mortality rates despite therapeutic advances. The pathogenesis of ALI and ARDS is similar to that of sepsis, as these disease states involve uncontrolled host defense responses that lead to inflammation, endothelial damage, enhanced coagulation, diminished fibrinolysis, and fibroproliferation. Recent studies of anticoagulants have shown positive outcomes in patients with severe sepsis. In addition, emerging evidence suggests that the use of anticoagulants, such as tissue factor pathway inhibitor, antithrombin, thrombomodulin, heparin, activated protein C, and fibrinolytics (plasminogen activators and particularly tissue plasminogen activator), may be useful in the treatment of ALI and ARDS. Data from experimental models of sepsis, ALI, and ARDS indicate that some of these agents improve lung function and oxygenation. Although clinical data are less convincing than these findings, results from clinical trials may influence the design of future studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据